OncoMatch/Clinical Trials/NCT06581640

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Is NCT06581640 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CAR-T treatment for multiple myeloma.

Phase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityNCT06581640Data as of May 2026

Treatment: CAR-T treatment — To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Biomarker criteria

Required: BCMA (TNFRSF17) overexpression (positive)

Flow cytometry or histology confirms positive BCMA expression in myeloma cells

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: BCMA-targeted therapy

Previously received treatment targeting BCMA

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: within the last 6 weeks

Underwent autologous hematopoietic stem cell transplantation within the last 6 weeks

Cannot have received: experimental drug

Exception: within the last 3 months

Received other experimental drug treatments within the last 3 months

Lab requirements

Blood counts

ALC ≥0.5 ×10^9/L, PLT >30×10^9/L, Hb >80 g/L

Kidney function

creatinine clearance rate >30 mL/min

Liver function

ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L

Cardiac function

heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%

The patient has good liver, kidney, heart, and lung function: ALT and AST ≤2.5×ULN, those with liver involvement can be relaxed to ≤5×ULN; serum total bilirubin <34 μmol/L; creatinine clearance rate >30 mL/min; heart ejection fraction (EF) ≥40%, no pericardial effusion and significant arrhythmia; indoor SpO2 ≥92%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify